Manufacturing of bupivacaine multivesicular liposomes
Embodiments of the present disclosure relates to a new and improved large scale commercial manufacturing process of making bupivacaine multivesicular liposomes (MVLs). Batches of bupivacaine MVLs prepared by the new process have high yields, improved stabilities, and desired particle size distributions.
1. A method of treating or ameliorating pain in a subject in need thereof, comprising administering to the subject a composition of bupivacaine encapsulated multivesicular liposomes (MVLs) from batches comprising compositions of bupivacaine encapsulated MVLs, the composition comprising:
bupivacaine residing inside a plurality of internal aqueous chambers of MVLs separated by lipid membranes, wherein the lipid membranes comprise 1,2-dierucoylphosphatidylcholine (DEPC), 1,2-dipalmitoyl-sn-glycero-3-phospho-rac-(1-glycerol) (DPPG) or a salt thereof, cholesterol, and tricaprylin; and
an aqueous medium in which the bupivacaine encapsulated MVLs are suspended, wherein the aqueous medium also comprises unencapsulated bupivacaine;
the total bupivacaine concentration in the composition is from 12 mg/mL to 17 mg/mL;
wherein the batches are manufactured within a period of six months, and each of the batches has a volume of 100 liters to 300 liters;
wherein each batch has a cumulative percentage release of bupivacaine from 46% to 71% at a 24-hour time point, measured from two to six aliquots of each batch using a rotator-facilitated in vitro release assay for at least 48 hours, after storage of the aliquots of each batch at 2° C. to 8° C. for about 12 months from batch manufacture date; and
wherein an average rate of change in the cumulative percentage release of bupivacaine of the batches at the 24-hour time point is 0.05%/month to 0.5%/month after storage of the aliquots of each batch at 2° C. to 8° C. for about 12 months.
2. The method of claim 1 , wherein each of the batches has a volume of about 110 liters to about 250 liters.
3. The method of claim 1 , wherein the average rate of change in the cumulative percentage release of bupivacaine at the 24-hour time point is 0.08%/month to 0.5%/month.
4. The method of claim 3 , wherein the average rate of change in the cumulative percentage release of bupivacaine at the 24-hour time point is 0.1%/month to 0.4%/month.
5. The method of claim 1 , wherein each batch has a cumulative percentage release of bupivacaine from 60% to 85% at a 48-hour time point, and the average rate of change in the cumulative percentage release of bupivacaine at the 48-hour time point is −0.3%/month to 0.33%/month.
6. The method of claim 5 , wherein the average rate of change in the cumulative percentage release of bupivacaine at the 48-hour time point is −0.2%/month to 0.300%/month.
7. The method of claim 6 , wherein the average rate of change in the cumulative percentage release of bupivacaine at the 48-hour time point is from −0.18%/month to 0.28%/month.
8. The method of claim 1 , wherein the average rate of change in the cumulative percentage release of bupivacaine is based on three batches, and one batch is manufactured 10 or more days apart from at least one other batch.
9. The method of claim 1 , wherein the average rate of change in the cumulative percentage release of bupivacaine is based on two batches, and one batch is manufactured 10 or more days apart from the other batch.
10. The method of claim 1 , wherein the cumulative percentage release of bupivacaine of each batch is measured as the average of six aliquots from each batch.
11. The method of claim 1 , wherein the administration is via local infiltration to a surgical site to provide local analgesia.
12. The method of claim 1 , wherein the administration is via interscalene brachial plexus nerve block or femoral nerve block to provide regional analgesia.
13. The method of claim 1 , wherein the administration is via an adductor canal block or via a sciatic nerve block in the popliteal fossa to provide regional analgesia.
14. The method of claim 1 , wherein the composition has a volume of about 10 mL or about 20 mL for a single-dose administration.
15. The method of claim 1 , wherein the subject is from 6 to 17 years old, and the amount of bupivacaine administered is about 4 mg/kg and up to 233 mg.
16. A method of treating or ameliorating pain in a subject in need thereof, comprising administering to the subject a composition of bupivacaine encapsulated multivesicular liposomes (MVLs) from batches comprising compositions of bupivacaine encapsulated MVLs, the composition comprising:
bupivacaine residing inside a plurality of internal aqueous chambers of MVLs separated by lipid membranes, wherein the lipid membranes comprise 1,2-dierucoylphosphatidylcholine (DEPC), 1, 2-dipalmitoyl-sn-glycero-3-phospho-rac-(1-glycerol) (DPPG) or a salt thereof, cholesterol, and tricaprylin; and
an aqueous medium in which the bupivacaine encapsulated MVLs are suspended, wherein the aqueous medium also comprises unencapsulated bupivacaine;
the total bupivacaine concentration in the composition is from 12 mg/mL to 17 mg/mL;
wherein the batches are manufactured within a period of six months, and each of the batches has a volume of 100 liters to 300 liters;
wherein each batch has a cumulative percentage release of bupivacaine from 60% to 85% at a 48-hour time point, measured from two to six aliquots of each batch using a rotator-facilitated in vitro release assay for at least 48 hours, after storage of the aliquots of each batch at 2° C. to 8° C. for about 12 months from batch manufacture date; and
wherein an average rate of change in the cumulative percentage release of bupivacaine of the batches at the 48-hour time point is −0.18%/month to 0.33%/month after storage of the aliquots of each batch at 2° C. to 8° C. for about 12 months.
17. The method of claim 16 , wherein each of the batches has a volume of about 110 liters to about 250 liters.
18. The method of claim 16 , wherein the average rate of change in the cumulative percentage release of bupivacaine at the 48-hour time point is −0.15%/month to 0.300%/month.
19. The method of claim 18 , wherein the average rate of change in the cumulative percentage release of bupivacaine at the 48-hour time point is from −0.12%/month to 0.28%/month.
20. The method of claim 16 , wherein the average rate of change in the cumulative percentage release of bupivacaine is based on three batches, and one batch is manufactured 10 or more days apart from at least one other batch.
21. The method of claim 16 , wherein the average rate of change in the cumulative percentage release of bupivacaine is based on two batches, and one batch is manufactured 10 or more days apart from the other batch.
22. The method of claim 16 , wherein the cumulative percentage release of bupivacaine of each batch is measured as the average of six aliquots from each batch.
23. The method of claim 16 , wherein the administration is via local infiltration to a surgical site to provide local analgesia.
24. The method of claim 16 , wherein the administration is via interscalene brachial plexus nerve block or femoral nerve block to provide regional analgesia.
25. The method of claim 16 , wherein the administration is via an adductor canal block or via a sciatic nerve block in the popliteal fossa to provide regional analgesia.
26. The method of claim 16 , wherein the composition of bupivacaine encapsulated MVLs administered has a volume of 10 mL or 20 mL for a single-dose administration.
27. The method of claim 16 , wherein the administration is via a pen, an injector system, a needle and syringe, a subcutaneous injection port delivery system, or a catheter.
28. The method of claim 16 , wherein the subject is from 6 to 17 years old, and the amount of bupivacaine administered is about 4 mg/kg and up to 233 mg.